BGB-11417-302: a phase 3 trial testing sonrotoclax with zanubrutinib in adults with relapsed or refractory mantle cell lymphoma

This trial aims to compare sonrotoclax with zanubrutinib against zanubrutinib with a placebo in people with mantle cell lymphoma (MCL) which are returned after (relapsed) or not responded to (refractory) treatment.

You can share the following clinicaltrials.gov identifier with your medical team so they can find out more about the trial: NCT06742996

Trial aim and background 

The aim of this trial is to test how well the treatment sonrotoclax works when given with zanubrutinib in people with relapsed or refractory MCL. It will be compared against zanubrutinib given with a placebo. It will also test how safe the combination of sonrotoclax and zanubrutinib is.

Sonrotoclax is a BCL2 blocker which destroys cancer cells by stopping them grow and survive
Zanubrutinib is a type of targeted treatment called a BTK inhibitor. This blocks a protein called Bruton’s tyrosine kinase which is needed for B-cells to multiply.

Who can enter

Adults with mantle cell lymphoma who have received between 1 and 5 lines of treatment previously may be eligible for this trial.

Locations

Recruitment is taking place at the following UK locations:

  • Beatson West of Scotland Cancer Centre, Glasgow
  • Churchill Hospital Oxford University Hospital NHS Trust, Headington
  • Clatterbridge Cancer Centre, Wirral
  • Derriford Hospital, Plymouth
  • The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth
  • University College Hospital, London    

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at:

https://clinicaltrials.gov/study/NCT06742996

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.